Search

Your search keyword '"Nakatsumi, Hiroshi"' showing total 7 results
Start Over Author "Nakatsumi, Hiroshi" Publication Year Range Last 3 years
7 results on '"Nakatsumi, Hiroshi"'

1. Results of a multicenter retrospective cohort study evaluating the safety and efficacy of FTD/TPI plus ramucirumab in advanced gastric cancer (HGCSG2302).

Author

Yoshikawa, Ayumu, Nakamura, Takeaki, Sawada, Kentaro, Ishiguro, Atsushi, Motoo, Iori, Sonoda, Yuki, Suzuki, Kazuhiro, Nakatsumi, Hiroshi, Hosokawa, Ayumu, Ishii, Takahiro, Ito, Ken, Nakamura, Michio, Hatanaka, Kazuteru, Meguro, Takashi, Sogabe, Susumu, Sasaki, Yusuke, Nakano, Shintaro, Muranaka, Tetsuhito, Yuki, Satoshi, and Komatsu, Yoshito

Published
2025
Full Text
View/download PDF

2. A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses.

Author

Nakatsumi, Hiroshi, Harada, Kazuaki, Yuki, Satoshi, Ishiguro, Atsushi, Sawada, Kentaro, Sogabe, Susumu, Ando, Takayuki, Sasaki, Yusuke, Yoshikawa, Ayumu, Nakamura, Michio, Dazai, Masayoshi, Tateyama, Miki, Muto, Osamu, Kotaka, Masahito, Sagawa, Tamotsu, Muranaka, Tetsuhito, Hatanaka, Kazuteru, Takagi, Ryo, Sakata, Yuh, and Komatsu, Yoshito

Published
2025
Full Text
View/download PDF

3. Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Author

Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, and Komatsu, Yoshito

Published
2022
Full Text
View/download PDF

4. A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801.

Author

Nakatsumi, Hiroshi, Komatsu, Yoshito, Harada, Kazuaki, Kawamoto, Yasuyuki, Yuki, Satoshi, Sawada, Kentaro, Ishiguro, Atsushi, Sogabe, Susumu, Ando, Takayuki, Sasaki, Yusuke, Yoshikawa, Ayumu, Nakamura, Michio, Dazai, Masayoshi, Tateyama, Miki, Muto, Osamu, Kotaka, Masahito, Sagawa, Tamotsu, Muranaka, Tetsuhito, Hatanaka, Kazuteru, and Takagi, Ryo

Subjects
JAPANESE people, FEBRILE neutropenia, COLORECTAL cancer, CANCER chemotherapy, OVERALL survival
Abstract

Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti‐epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open‐label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5‐fluorouracil [5‐FU] 400 mg/m2, and infusional 5‐FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression‐free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6‐month PFS rate was 58.8% (90% confidence interval [CI], 45.7%–72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5–11.0 months) and 18.8 months (95% CI, 12.9–26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0–36.0%) and disease control rate was 88.4% (95% CI, 74.9–96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.

Author

Ishiguro, Atsushi, Nakatsumi, Hiroshi, Harada, Kazuaki, Yuki, Satoshi, Sawada, Kentaro, Sogabe, Susumu, Ando, Takayuki, Sasaki, Yusuke, Yoshikawa, Ayumu, Nakamura, Michio, Dazai, Masayoshi, Tateyama, Miki, Muto, Osamu, Kotaka, Masahito, Sagawa, Tamotsu, Hatanaka, Kazuteru, Takagi, Ryo, Sakata, Yuh, and Komatsu, Yoshito

Published
2024
Full Text
View/download PDF

6. Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

Author

Nakatsumi, Hiroshi, primary, Komatsu, Yoshito, additional, Muranaka, Tetsuhito, additional, Yuki, Satoshi, additional, Kawamoto, Yasuyuki, additional, Harada, Kazuaki, additional, Dazai, Masayoshi, additional, Tateyama, Miki, additional, Sasaki, Yusuke, additional, Miyagishima, Takuto, additional, Tsuji, Yasushi, additional, Katagiri, Masaki, additional, Nakamura, Michio, additional, Sogabe, Susumu, additional, Hatanaka, Kazuteru, additional, Meguro, Takashi, additional, Kobayashi, Tomoe, additional, Ishiguro, Atsushi, additional, Muto, Osamu, additional, Shindo, Yoshiaki, additional, Kotaka, Masahito, additional, Ando, Takayuki, additional, Takagi, Ryo, additional, Sakamoto, Naoya, additional, and Sakata, Yu, additional

Published
2022
Full Text
View/download PDF

7. O15-2 HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy

Author

Yokoyama, Tatsuya, primary, Ito, Ken, additional, Yuki, Satoshi, additional, Nakatsumi, Hiroshi, additional, Ando, Takayuki, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Iwanaga, Ichiro, additional, Hatanaka, Kazuteru, additional, Sato, Atsushi, additional, Matsumoto, Ryusuke, additional, Shindo, Yoshiaki, additional, Tateyama, Miki, additional, Muranaka, Tetsuhito, additional, Katagiri, Masaki, additional, Yokota, Isao, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results